PSA Today 4 Jan: Opening 2023 on a down note / Lecanemab's Congressional report: concern / A rethink of drug accelerated approval? / Global console sales – Nikkei 225 -1.45%
Japan Market Comment by Pelham Smithers and Julie BooteTags: Eisai (4523 JT), Biogen (BIIB US), Sysmex (6869 JT) Corp, Ono Pharmaceutical (4528 JT), Daiichi Sankyo (4568 JT), Sony (6758 JT), Microsoft (MSFT US), Apple (AAPL US), Tesla (TSLA US), BioArctic (BIOAB SS), Eli Lilly (LLY US), Nintendo (7974 JT)
Main Points
• Tokyo opens 2023 on down note as yen strength, economic worries play on sentiment
• Congressional report on Aduhelm puts accelerated approval of lecanemab at risk
• Risk of a rethink of the accelerated approval process
• Global console sales +11% YoY in week to 10 Dec
Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods.
PSA produces both company and sector reports. The focus of PSA’s research is to identify winners and losers as new technologies impact the top and bottom lines of corporations. Critical to our research is the clear explanation of how these new technologies work and how they impact companies and industries.
The founding partners have worked closely together for twenty years and the team has more than doubled in size since 2012.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.